Vaccine Technologies: US FDA Isn’t Afraid Of Needle-Free Delivery, But It Takes Time To Develop, Woodcock Says

The agency is interested in alternative formulations for COVID-19 inoculations, but pushed the traditional injection presentation because it was easier to develop quickly.

Nasal COVID-19 vaccine formulation
A nasal COVID-19 vaccine formulation is one of several new technologies under consideration, Acting FDA Commissioner Janet Woodcock said. • Source: Alamy

New vaccine technologies are not being ignored, but take longer to develop, which is why traditional platforms were prioritized, said Janet Woodcock, acting US Food and Drug Administration commissioner.

Sen. Lisa Murkowski, R-Alaska, did not give specifics, but indicated during a 4 November Senate Health, Education, Labor and Pensions...

More from Vaccines

More from Pink Sheet

‘Unprecedented Story’: Revoked EU Marketing Authorization Fails To Thwart Translarna Sales

 

PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.

UK HRA Sets Targets For Digital Overhaul, Trial Transparency And Trust

 
• By 

The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.

Valneva Expects UK And France to Lift Ixchiq Age Restriction Following EMA Decision

 

Other authorities are expected to mirror the European Medicines Agency’s decision to lift the temporary restriction it placed on using Valneva’s chikungunya vaccine in people aged 65 years and older.